Views & Analysis | Perspectives on pharma industry issues

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Articles

Using the metabolic mindset to boost healthcare provider con...

Jessica Brueggeman highlights how behaviour patterns can determine how patients will respond to treatment approaches. Is it time we stopped to recognise our patients’ motivations rather than apply a one-size-fits-all approach? Chronic, non-communicable diseases pose a serious burden to patients, healthcare providers and healthcare systems. While patients’ interactions...

Articles

Enterprise 2.0: part 5 – People. Plan. Platform.

René van den Bos rounds up his series with a look at the target audience, the master plan and the technology. In the previous episode we talked about how to with Enterprise 2.0 in your company. We’ve done an internal analysis of the organisation through...

Articles

Tunnah’s musings: what’s in it for me?

Inspired by the discussion from the recent healthcare social media global camp, Paul Tunnah asks if we need to be more selfish to produce game-changing healthcare solutions. At the heart of it we’re all selfish creatures, we’re all driven by our own internal desires. Don’t worry – this is not going to be a rant on humanity, but it is…

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.